Anthem Biosciences Limited (NSE:ANTHEM)
India · Delayed Price · Currency is INR 858.50
-0.10 (-0.01%)
Oct 1, 2026, 3:29 PM IST
Anthem Biosciences Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 481,954 | 368,557 | - | - | - | - | |
Market Cap Growth | 12.74% | - | - | - | - | - |
Enterprise Value | 473,108 | 359,342 | - | - | - | - |
Last Close Price | 855.75 | 654.54 | - | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 84.66 | 62.28 | - | - | - | - |
Forward PE | 64.12 | 54.93 | - | - | - | - |
PS Ratio | 24.01 | 17.31 | - | - | - | - |
PB Ratio | 15.84 | 12.11 | - | - | - | - |
P/TBV Ratio | 15.84 | 12.12 | - | - | - | - |
P/FCF Ratio | 76.10 | 58.20 | - | - | - | - |
P/OCF Ratio | 57.07 | 43.64 | - | - | - | - |
PEG Ratio | 3.21 | 2.29 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 23.57 | 16.88 | - | - | - | - |
EV/EBITDA Ratio | 58.48 | 42.77 | - | - | - | - |
EV/EBIT Ratio | 71.25 | 50.72 | - | - | - | - |
EV/FCF Ratio | 74.70 | 56.74 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.02 | 0.02 | 0.05 | 0.12 | 0.07 | 0.04 |
Debt / EBITDA Ratio | 0.07 | 0.06 | 0.17 | 0.47 | 0.29 | 0.10 |
Debt / FCF Ratio | - | 0.09 | 12.13 | - | 1.08 | 0.33 |
Net Debt / Equity Ratio | -0.29 | -0.29 | -0.15 | -0.21 | -0.41 | -0.41 |
Net Debt / EBITDA Ratio | -1.10 | -1.05 | -0.55 | -0.80 | -1.63 | -0.96 |
Net Debt / FCF Ratio | - | -1.40 | -39.65 | 2.70 | -6.06 | -3.12 |
Asset Turnover | - | 0.68 | 0.71 | 0.64 | 0.58 | 0.94 |
Inventory Turnover | - | 3.68 | 2.83 | 3.67 | 3.81 | 9.15 |
Quick Ratio | - | 4.70 | 2.89 | 3.35 | 6.78 | 4.18 |
Current Ratio | - | 5.54 | 4.56 | 4.38 | 8.07 | 4.83 |
Return on Equity (ROE) | - | 21.71% | 20.82% | 20.04% | 24.88% | 39.44% |
Return on Assets (ROA) | - | 14.20% | 14.12% | 12.03% | 12.81% | 24.49% |
Return on Invested Capital (ROIC) | 22.65% | 24.24% | 22.71% | 25.61% | 31.47% | 56.74% |
Return on Capital Employed (ROCE) | - | 22.80% | 23.70% | 20.60% | 20.10% | 37.30% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 1.20% | 1.61% | - | - | - | - |
FCF Yield | 1.31% | 1.72% | - | - | - | - |
Dividend Yield | 0.23% | 0.31% | - | - | - | - |
Buyback Yield / Dilution | -1.42% | -1.03% | 0.96% | 0.61% | 0.00% | -4.33% |
Total Shareholder Return | -1.19% | -0.72% | 0.96% | 0.61% | - | -4.33% |